{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:35:41Z","timestamp":1784684141567,"version":"3.55.0"},"reference-count":43,"publisher":"Bentham Science Publishers Ltd.","issue":"4","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>As the World faces unprecedented pandemic caused by SARS-CoV-2 virus,\nrepositioning of existing drugs to treatment of COVID-19 disease is urgently awaited, provided\nthat high quality scientific evidence supporting safety and efficacy in this new indication is gathered.\nEfforts concerning drugs repositioning to COVID-19 were mostly focused on antiviral drugs,\nor drugs targeting the late phase of the disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Based on published research, the pharmacological activities of fluvoxamine and amantadine,\ntwo well-known drugs widely used in clinical practice for psychiatric and neurological diseases,\nrespectively, have been reviewed, with a focus on their potential therapeutic importance in the\ntreatment of COVID-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result:<\/jats:title>\n<jats:p>Several preclinical and clinical reports were identified suggesting that these two drugs\nmight exert protective effects in the early phases of COVID-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Preclinical and early clinical evidence are presented indicating that these drugs hold\npromise to prevent COVID-19 progression when administered early during the course of infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x19666210729123734","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T04:34:51Z","timestamp":1627619691000},"page":"777-781","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluvoxamine and Amantadine: Central Nervous System Acting Drugs\nRepositioned for COVID-19 as Early Intervention"],"prefix":"10.2174","volume":"20","author":[{"given":"Konrad","family":"Rejdak","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Grieb","sequence":"additional","affiliation":[{"name":"Department of Experimental Pharmacology,\nMossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"Wouters O.J.","year":"2020","unstructured":"Wouters O.J.; McKee M.; Luyten J.; Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 2020,323(9),844-853","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/adt.2015.29011.tiodrrr","volume":"13","author":"Oprea T.I.","year":"2015","unstructured":"Oprea T.I.; Overington J.P.; Computational and practical aspects of drug repositioning. Assay Drug Dev Technol 2015,13(6),299-306","journal-title":"Assay Drug Dev Technol"},{"key":"ref=4","first-page":"1","volume":"3","author":"Jamalipour S.G.","year":"2020","unstructured":"Jamalipour S.G.; Iravani S.; Potential inhibitors of SARS-CoV-2: Recent advances. J Drug Target 2020,3,1-16","journal-title":"J Drug Target"},{"key":"ref=5","first-page":"1","volume":"30","author":"Payandeh Z.","year":"2020","unstructured":"Payandeh Z.; The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. Expert Rev Anti Infect Ther 2020,30,1-13","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12038-020-00067-w","volume":"45","author":"Saxena A.","year":"2020","unstructured":"Saxena A.; Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci 2020,45,87","journal-title":"J Biosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bsheal.2021.01.001","volume":"3","author":"Ungogo M.A.","year":"2021","unstructured":"Ungogo M.A.; Mohammed M.; Umar B.N.; Bala A.A.; Khalid G.M.; Review of pharmacologic and immunologic agents in the management of COVID-19. Health 2021,3(3),148-155","journal-title":"Health"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/00003495-198632040-00002","volume":"32","author":"Benfield P.","year":"1986","unstructured":"Benfield P.; Ward A.; Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986,32(4),313-334","journal-title":"Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00406-020-01231-x","volume":"271","author":"Hashimoto K.","year":"2021","unstructured":"Hashimoto K.; Repurposing of CNS drugs to treat COVID-19 infection: Targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci 2021,271(2),249-258","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=10","first-page":"29","volume":"247","author":"Weissman A.D.","year":"1988","unstructured":"Weissman A.D.; Su T.P.; Hedreen J.C.; London E.D.; Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther 1988,247(1),29-33","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/138161207779313740","volume":"13","author":"Collier T.L.","year":"2007","unstructured":"Collier T.L.; Waterhouse R.N.; Kassiou M.; Imaging sigma receptors: Applications in drug development. Curr Pharm Des 2007,13(1),51-72","journal-title":"Curr Pharm Des"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri.2016.62","volume":"16","author":"Grootjans J.","year":"2016","unstructured":"Grootjans J.; Kaser A.; Kaufman R.J.; Blumberg R.S.; The unfolded protein response in immunity and inflammation. Nat Rev Immunol 2016,16(8),469-484","journal-title":"Nat Rev Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5266","volume":"11","author":"Rosen D.A.","year":"2019","unstructured":"Rosen D.A.; Seki S.M.; Fern\u00e1ndez-Casta\u00f1eda A.; Beiter R.M.; Eccles J.D.; Woodfolk J.A.; Gaultier A.; Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med 2019,11(478)","journal-title":"Sci Transl Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-020-10197-8","volume":"1","author":"Santerre M.","year":"2020","unstructured":"Santerre M.; Arjona S.P.; Allen C.N.; Shcherbik N.; Sawaya B.E.; Why do SARS-CoV-2 NSPs rush to the ER? J Neurol 2020,1,1-10","journal-title":"J Neurol"},{"key":"ref=15","first-page":"705","volume":"41","author":"So J.S.","year":"2018","unstructured":"So J.S.; Roles of endoplasmic reticulum stress in immune responses. Mol Cells 2018,41(8),705-716","journal-title":"Mol Cells"},{"key":"ref=16","author":"Grieb P.","unstructured":"Grieb P.; Swiatkiewicz M.; Prus K.; Rejdak K.;  Hypoxia may be a determinative factor in COVID-19 progression","journal-title":"Hypoxia may be a determinative factor in COVID-19 progression"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13046-020-01824-3","volume":"40","author":"Akman M.","year":"2021","unstructured":"Akman M.; Belisario D.C.; Salaroglio I.C.; Kopecka J.; Donadelli M.; De Smaele E.; Riganti C.; Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. J Exp Clin Cancer Res 2021,40(1),28","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"Lenze E.J.","year":"2020","unstructured":"Lenze E.J.; Mattar C.; Zorumski C.F.; Stevens A.; Schweiger J.; Nicol G.E.; Miller J.P.; Yang L.; Yingling M.; Avidan M.S.; Reiersen A.M.; Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA 2020,324(22),2292-2300","journal-title":"JAMA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1083\/jcb.133.4.733","volume":"133","author":"Sakaguchi T.","year":"1996","unstructured":"Sakaguchi T.; Leser G.P.; Lamb R.A.; The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. J Cell Biol 1996,133(4),733-747","journal-title":"J Cell Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","volume":"39","author":"Lampejo T.","year":"2020","unstructured":"Lampejo T.; Influenza and antiviral resistance: An overview. Eur J Clin Microbiol Infect Dis 2020,39(7),1201-1208","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=21","first-page":"11","volume":"7","author":"Hesselink J.M.K.","year":"2017","unstructured":"Hesselink J.M.K.; Amantadine and phenytoin: patent protected cases of drug repositioning. Clin Investig (Lond) 2017,7,11-16","journal-title":"Clin Investig (Lond)"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007548","volume":"13","author":"Dey D.","year":"2019","unstructured":"Dey D.; Siddiqui S.I.; Mamidi P.; Ghosh S.; Kumar C.S.; Chattopadhyay S.; Ghosh S.; Banerjee M.; The effect of amantadine on an ion channel protein from Chikungunya virus. PLoS Negl Trop Dis 2019,13(7)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/apt.12562","volume":"39","author":"Carre\u00f1o V.","year":"2014","unstructured":"Carre\u00f1o V.; Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther 2014,39(2),148-162","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00109-018-1631-z","volume":"96","author":"Xing W.","year":"2018","unstructured":"Xing W.; Huang P.; Lu Y.; Zeng W.; Zuo Z.; Amantadine attenuates sepsis-induced cognitive dysfunction possibly not through inhibiting toll-like receptor 2. J Mol Med (Berl) 2018,96(5),391-402","journal-title":"J Mol Med (Berl)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/biom9050191","volume":"9","author":"Nakano T.","year":"2019","unstructured":"Nakano T.; Hasegawa T.; Suzuki D.; Motomura E.; Okada M.; Amantadine combines astroglial system Xc- activation with glutamate\/NMDA receptor inhibition. Biomolecules 2019,9(5),191","journal-title":"Biomolecules"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/14656566.2019.1612365","volume":"20","author":"M\u00fcller T.","year":"2019","unstructured":"M\u00fcller T.; Kuhn W.; M\u00f6hr J.D.; Evaluating ADS5102 (amantadine) for the treatment of Parkinson\u2019s disease patients with dyskinesia. Expert Opin Pharmacother 2019,20(10),1181-1187","journal-title":"Expert Opin Pharmacother"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102533","volume":"46","author":"Ormstad H.","year":"2020","unstructured":"Ormstad H.; Simonsen C.S.; Broch L.; Maes D.M.; Anderson G.; Celius E.G.; Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways. Mult Scler Relat Disord 2020,46","journal-title":"Mult Scler Relat Disord"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/02699052.2020.1723697","volume":"34","author":"Ma H.M.","year":"2020","unstructured":"Ma H.M.; Zafonte R.D.; Amantadine and memantine: A comprehensive review for acquired brain injury. Brain Inj 2020,34(3),299-315","journal-title":"Brain Inj"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/jmv.25752","volume":"92","author":"Cimolai N.","year":"2020","unstructured":"Cimolai N.; Potentially repurposing adamantanes for COVID-19. J Med Virol 2020,92(6),531-532","journal-title":"J Med Virol"},{"key":"ref=30","first-page":"204","volume":"54","author":"Tipton P.W.","year":"2020","unstructured":"Tipton P.W.; Wszolek Z.K.; What can Parkinson\u2019s disease teach us about COVID-19? Neurol Neurochir Pol 2020,54(2),204-206","journal-title":"Neurol Neurochir Pol"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109755","volume":"140","author":"Abreu G.E.A.","year":"2020","unstructured":"Abreu G.E.A.; Aguilar M.E.H.; Covarrubias D.H.; Dur\u00e1n F.R.; Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses 2020,140","journal-title":"Med Hypotheses"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106004","volume":"55","author":"Smieszek S.P.","year":"2020","unstructured":"Smieszek S.P.; Przychodzen B.P.; Polymeropoulos M.H.; Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. Int J Antimicrob Agents 2020,55(6)","journal-title":"Int J Antimicrob Agents"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102163","volume":"42","author":"Rejdak K.","year":"2020","unstructured":"Rejdak K.; Grieb P.; Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord 2020,42","journal-title":"Mult Scler Relat Disord"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/geriatrics6010010","volume":"6","author":"Yu Y.","year":"2021","unstructured":"Yu Y.; Travaglio M.; Popovic R.; Leal N.S.; Martins L.M.; Alzheimer\u2019s and parkinson\u2019s diseases predict different COVID-19 outcomes: A UK biobank study. Geriatrics (Basel) 2021,6(1),10","journal-title":"Geriatrics (Basel)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1007\/s43440-020-00168-1","volume":"72","author":"Aranda-Abreu G.E.","year":"2020","unstructured":"Aranda-Abreu G.E.; Aranda-Mart\u00ednez J.D.; Ara\u00fajo R.; Hern\u00e1ndez-Aguilar M.E.; Herrera-Covarrubias D.; Rojas-Dur\u00e1n F.; Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep 2020,72(6),1538-1541","journal-title":"Pharmacol Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.arcmed.2020.06.009","volume":"51","author":"Ara\u00fajo R.","year":"2020","unstructured":"Ara\u00fajo R.; Aranda-Mart\u00ednez J.D.; Aranda-Abreu G.E.; Amantadine treatment for people with COVID-19. Arch Med Res 2020,51(7),739-740","journal-title":"Arch Med Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41594-020-00536-8","volume":"27","author":"Mandala V.S.","year":"2020","unstructured":"Mandala V.S.; McKay M.J.; Shcherbakov A.A.; Dregni A.J.; Kolocouris A.; Hong M.; Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol 2020,27(12),1202-1208","journal-title":"Nat Struct Mol Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1021\/acsptsci.0c00172","volume":"3","author":"Baig A.M.","year":"2020","unstructured":"Baig A.M.; Khaleeq A.; Syeda H.; Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2. ACS Pharmacol Transl Sci 2020,3(6),1430-1433","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2020.22813","volume":"324","author":"Kim P.S.","year":"2020","unstructured":"Kim P.S.; Read S.W.; Fauci A.S.; Therapy for early COVID-19: a critical need. JAMA 2020,324(21),2149-2150","journal-title":"JAMA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00702-021-02306-2","volume":"128","author":"Danysz W.","year":"2021","unstructured":"Danysz W.; Dekundy A.; Scheschonka A.; Riederer P.; Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. J Neural Transm (Vienna) 2021,128(2),127-169","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=41","first-page":"D5018","volume":"164","author":"Luyten J.","year":"2020","unstructured":"Luyten J.; McKee M.; Wouters O.J.; How much does research and development of a drug cost? A call for more transparency. Ned Tijdschr Geneeskd 2020,164,D5018","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref=42","year":"2020","unstructured":"Clinical Trials Arena Eli Lilly\u2019s monoclonal antibody bamlanivimab value allows payer grace for Covid-19. Available from:clinicaltrialsarena.com 18 November 2020.2020"},{"key":"ref=43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc1518","volume":"6","author":"Ayres J.S.","year":"2020","unstructured":"Ayres J.S.; Surviving COVID-19: A disease tolerance perspective. Sci Adv 2020,6","journal-title":"Sci Adv"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666210729123734","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195136\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666210729123734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T01:53:07Z","timestamp":1658281987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195136\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x19666210729123734","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}